Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Orthobiologics (2019) |
Auteurs : | Tenaya A. West ; Mitzi L. Williams |
Type de document : | Article |
Dans : | Clinics in Podiatric Medicine and Surgery (Vol. 36, n° 4, October 2019) |
Article en page(s) : | p. 609-626 |
Note générale : | doi:10.1016/j.cpm.2019.06.006 |
Langues: | Anglais |
Descripteurs : |
HE Vinci Allogreffes ; Autogreffes ; Cheville ; Chirurgie générale ; Pied ; Plasma riche en plaquettes ; Substituts osseux |
Mots-clés: | Orthobiologie |
Résumé : |
The use of orthobiologics in foot and ankle pathology is an exciting field with significant potential. However, many available products lack peer-reviewed evidence, and, for those that do, the literature has high variation in techniques, study populations, and outcome measures. This leads to conflicting results that may obscure the true indications for respective products. Recent systematic reviews of PRP and BMAC in clinical orthopedic literature found that only 16% of articles on PRP and 14% of articles on BMAC quantitatively reported the composition of the final product.45 No studies on BMAC and only 10% of studies on PRP provided a reproducible preparation technique in their methods.45 Various classification systems have been suggested to standardize future PRP trials.5, 133, 134, 135 This act of standardizing the reporting of technique and results should be applied to all orthobiologic products, allowing for a clearer interpretation of their true efficacy. A focus should be maintained on completing large, high-quality prospective trials to elucidate the true indications for all emerging orthobiologic products in the foot and ankle.
It is important to recognize the concerns and unknown long-term reactions with utilization of osteogenic or osteoinductive products in the use of pediatrics. Children developing and undergoing osseous maturation may respond very differently to these products. At present, structural allografts are FDA approved in pediatric surgery, but ongoing research is needed to support further products. |
Disponible en ligne : | Oui |
En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S0891842219300436 |